phosphorylcholine has been researched along with Nausea in 5 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas." | 9.07 | Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study. ( Kok, T; Krzemieniecki, K; Mouridsen, H; Poveda, A; van Glabbeke, M; van Pottelsberghe, C; Verweij, J, 1993) |
| "34 patients with metastatic colorectal cancer were treated with the ether lipid miltefosine (hexadecylphosphocholine)." | 9.07 | Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. ( Planting, AS; Stoter, G; Verweij, J, 1993) |
| "The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas." | 5.07 | Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study. ( Kok, T; Krzemieniecki, K; Mouridsen, H; Poveda, A; van Glabbeke, M; van Pottelsberghe, C; Verweij, J, 1993) |
| "34 patients with metastatic colorectal cancer were treated with the ether lipid miltefosine (hexadecylphosphocholine)." | 5.07 | Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. ( Planting, AS; Stoter, G; Verweij, J, 1993) |
| "Oral perifosine was tolerable up to 600mg/week in cancer patients when administered with meal and prophylactic antiemetics." | 2.75 | First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. ( Berdel, W; Engel, J; Hanauske, AR; Mross, K; Sindermann, H; Unger, C, 2010) |
| "Miltefosine is an oral medication with anti-leishmania activity and may increase the cure rates and improve compliance." | 2.75 | Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. ( Ampuero, J; Carvalho, EM; Guimarães, LH; Machado, PR; Penna, G; Rocha, AT; Schriefer, A; Sousa, RS; Talhari, A; Villasboas, L, 2010) |
| "In patients with breast cancer and skin metastases, topically applied miltefosine solution yields at least partial regression of the lesions in approximately a quarter of patients when used as an adjunct to standard treatment (surgery, radiotherapy, systemic chemotherapy or hormone therapy) or when standard treatments are contraindicated." | 1.30 | Miltefosine: new preparation. Solution for cutaneous application. ( , 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Unger, C | 1 |
| Berdel, W | 1 |
| Hanauske, AR | 1 |
| Sindermann, H | 1 |
| Engel, J | 1 |
| Mross, K | 1 |
| Machado, PR | 1 |
| Ampuero, J | 1 |
| Guimarães, LH | 1 |
| Villasboas, L | 1 |
| Rocha, AT | 1 |
| Schriefer, A | 1 |
| Sousa, RS | 1 |
| Talhari, A | 1 |
| Penna, G | 1 |
| Carvalho, EM | 1 |
| Verweij, J | 2 |
| Krzemieniecki, K | 1 |
| Kok, T | 1 |
| Poveda, A | 1 |
| van Pottelsberghe, C | 1 |
| van Glabbeke, M | 1 |
| Mouridsen, H | 1 |
| Planting, AS | 1 |
| Stoter, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Trial to Assess Efficacy and Safety of Orally Administered Miltefosine in Brazilian Patients With Cutaneous Leishmaniasis Compared to the Standard Care as Active Control[NCT00600548] | Phase 2 | 180 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for phosphorylcholine and Nausea
| Article | Year |
|---|---|
First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours.
Topics: Abdominal Pain; Administration, Oral; Antiemetics; Antineoplastic Agents; Diarrhea; Dose-Response Re | 2010 |
Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.
Topics: Abdominal Pain; Administration, Oral; Adolescent; Adult; Aged; Antimony; Antiprotozoal Agents; Brazi | 2010 |
Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Male; Middle Aged; Nausea; Phosphorylcholin | 1993 |
Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Leuk | 1993 |
1 other study available for phosphorylcholine and Nausea
| Article | Year |
|---|---|
Miltefosine: new preparation. Solution for cutaneous application.
Topics: Administration, Cutaneous; Antineoplastic Agents; Blood Cell Count; Breast Neoplasms; Clinical Trial | 1998 |